Effects of Dapagliflozin on Progression of Alport Syndrome

Active, not recruitingOBSERVATIONAL

Enrollment

222

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions

Alport Syndrome

Interventions

DRUG

Dapagliflozin 10mg Tab

Dapagliflozin 10mg daily plus RAS inhibitor

Trial Locations (1)

Jinling Hospital, Nanjing

All Listed Sponsors

lead

Nanjing University School of Medicine

OTHER

NCT06226896 - Effects of Dapagliflozin on Progression of Alport Syndrome | Biotech Hunter | Biotech Hunter